News

Annual report from the American Cancer Society says HIV is an underlying factor in a handful of cancer diagnoses.

The proportion of cancer patients who are 50-64 is increasing while the proportion of those 65 and older is shrinking, according to American Cancer Society researchers.

Overall cancer mortality in the U.S. continues to decline but there are some worrying trends in incidence and wide racial disparities.

States can use federal money that would otherwise support ACA marketplace premium tax credits to set up programs that offer health insurance to low-income people whose incomes are too high to make them eligible for Medicaid.

The smartphone app is currently under investigation in the CONVOKE study as a pharmaceutical therapy, aiming to address the negative symptoms associated with adult schizophrenia.

A substantial reduction in claim costs can be persuasive and attention-grabbing, but without assurances of continuity of care and proper clinical oversight, the ultimate goal of positive patient health outcomes can be elusive — and costly.

The CAR T-cell therapy targets the CD19 protein ubiquitous on the surface of B cells, which are known to mediate various types of autoimmune diseases, including MS.

UnitedHealth Group executives attribute the increase of revenue at Optum Rx to the addition of new clients, expanded relationships with existing clients, and advancements in services.

UnitedHealth Group executives attribute the increase in revenue and earnings to growth at both its Optum and UnitedHealthcare divisions.

Researchers developed a new multi-cancer blood screening test to detect early-stage cancers and found it had a high level of accuracy.

Janssen Biotech's Remicade (infliximab), an FDA-approved tumor necrosis factor inhibitor since 1998 for Crohn's disease, has gained additional approvals for managing ulcerative colitis and rheumatoid arthritis.

New sign-up rates for plan selections total 18%.

After anticipation of integrating two health systems for the last two years, Essentia Health and Marshfield Clinic Health System (MCHS) recently announced their merger will no longer be in effect.

The transaction is valued at about $575 million. The sale is part of Rite Aid’s restructuring plan after filing for bankruptcy in October 2023.

The Philadelphia-based insurer has selected four winners.

Research findings reported in Health Affairs today show that relatively small increases in out-of-pocket costs for HIV preexposure prophylaxis (PrEP) have a disproportionate effect on the proportion of people who don't get the prescription filled.

Adam Fein, founder of Drug Channels, said the acquisition will allow the company to upgrade its technology, grow the company and provide live and in-person events.

The large pharmacy benefit managers have switched up their coverage of biosimilars, especially the biosimilars to Humira (adalimumab).

The American Gastroenterological Association recommendations do not take a stand for or against using probiotics for those with intermittent pouchitis.

COVID-19 vaccines are currently administered intramuscularly. Studies indicate that intramuscular vaccine administration may not effectively generate antibodies and T cells against SARS-CoV-2 in the respiratory tract mucosa.

Adam Fein, founder of Drug Channels, said the acquisition will allow the company to upgrade its technology, grow the company and provide live and in-person events.

Lipoprotein(a) is a cardiovascular disease risk factor that does not change with diet and exercise. There are no FDA-approved treatments, but two candidates are in phase 3 trials.

We caught up recently with William Shrank, M.D., a longtime member of the Managed Healthcare Executive editorial advisory board. Shrank has held several executive positions with health insurers, most recently Humana. He is now a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California.

The 10 drugs selected by CMS for price negotiation are priced about three times higher in the United States than in other countries, finds a new study by the Commonwealth Fund.

Results point to the benefit of adding Darzalex (daratumumab) to Velcade-Revlimid-dexamethasone triplet therpay, although serious side effects seem be slightly more common when Darzalex is added.

Trial results revealed that tumors shrank in 40% of patients who received the 10-mg dose of tarlatamab and in about 32% of those who received the 100-mg dose.

Results reported in JAMA Psychiatry today show no difference in effectivenes between at-home cranial stimulation and sham treatment.

A subset of natural killer cells may be a potential target for the development of agents protective against MS.